abstract |
The present invention is directed to novel 5-oxazolidin-2-one substituted 1, 3,8 -thazaspiro [4.5 ]decan-4 -one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions. |